pila_board

PILA PHARMA AB (PILA) wishes to develop an oral anti-diabetic agent that effectively controls hyperglycemia and bodyweight gain in type 2 diabetes without increasing the risk of having cardiovascular disease.

The TRPV1 target (also called the ‘chili-receptor’) has demonstrated applications across pain and inflammatory diseases and hypothetically plays a role in diabetes as well.

PILA PHARMA owns issued use-patents that give the exclusive right to treat diabetes and obesity with antagonists of the TRPV1 receptor.

In 2016, the company acquired a TRPV1 antagonist asset including the clinical ready and safe development candidate XEN-D0501 that entered the first clinical trials in type-2 diabetic patients in 2017.